TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←

$ATAI

Atai Life Sciences
···
sign in to save

Atai Life Sciences develops psychedelic-inspired therapies targeting mental health disorders through clinical trials.

sentiment mix
bull 100%bear 0%neu 0%

signal summary

latest high-conviction thesis
Angermayer's main holding Atai brings psychedelic medicines to mainstream psychiatry▾

Psychedelic compounds have near-zero downside when used medically with clinicians and can cure mental health issues; Atai is building the full suite of psychedelic medicines with first approvals expected early next year.

christian angermayerT1Generating Alpha Podcast2026-05-11
confidence 88 / 100impact High
key themes
  • Life Sciences & Drug Development100%
  • Human Performance Enhancement100%
  • Longevity & Aging100%

bull thesis · 1

95 / 100
  • •Angermayer's main holding Atai brings psychedelic medicines to mainstream psychiatry

bear thesis · 0

—
  • — none —

mentions · 1

Generating Alpha PodcastEpisode 53: Christian Angermayer - Founder of Apeiron Investment Group1 mentions · 1▲ 0▼ 0○ · 5 months ago
0:006:0012:0018:0025:00